anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an external-application nursing medical ice bag for the parotitis. Existing ice bags have many shortcomings that most ice bags are frozen to be blocky when the ice bags are frozen, the ice bags can not be completely attached to the ice application portion especially the joints or the curved portions of the body in the emergency use process, specific drug therapy effect can not be achieved basically, refrigerating fluid inside the ice bags leaks and the wound portions are infected. The external-application nursing medical ice bag for the parotitis comprises an inner bag and an outer bag. A main containing cavity is formed inside the inner bag. An annular interlayer cavity is formed between the inner bag and the outer bag. The main containing cavity is filled with a mixed solution. The interlayer cavity is filled with compound Chinese medicine. The mixed solution is a solution formed by mixing deionized water, glycerol and a methylrosanilinium chloride solution according to a certain ratio. The compound Chinese medicine is a fine powder mixture formed by mixing lilac daphne flower bud roots, cactuses and borneol according to a certain ratio. According to the ingenious design in structure and optimized matching in content, the external-application nursing medical ice bag for the parotitis has the advantages of being capable of being attached to the ice application portion closely and obvious in therapy effect.
PROBLEM TO BE SOLVED: To provide a novel composition and method for treating a soft tissue, and particularly injuries of a soft tissue such as sprain or contusion.SOLUTION: The invention provides a method for treating a soft tissue with the use of HA and botulinum toxin together to form a supportive physical scaffold around a desired soft tissue. In one embodiment, provided is a method for treating sprain and/or contusion and the like in a human or an animal in need of treatment of soft tissue trauma. The method comprises the combined administration of hyaluronic acid and botulinum toxin. The hyaluronic acid and botulinum toxin are administered around the soft tissue to be treated. A soft tissue may be selected from, but not limited to, muscle, fascia, tendon and ligament. A soft tissue may also include fascia, fibrous tissues, fat and muscles.
PURPOSE:To enable microemulsification at ordinary temp. or under the temp. conditions where an oil-phase component is uniformly dissolved, by mixing the gastric mucous membrane mucin of a mammal, a water-soluble polyhydroxy compd., and an oil-phase component to prepare the emulsion composition. CONSTITUTION:The gastric mucous membrane mucin of a mammal, a water-soluble polyhydroxy compds., and an oil-phase component are mixed to prepare an emulsion composition, and the emulsion composition and a water-soluble component are mixed to obtain an oil-in-water emulsion composition. In the emulsion composition, the system consisting of the glycoprotein (mucin) contg. sialic acid, a giant molecule contg. the gastric membrane mucin of a mammal extremely safe for the human body, and having 1X10-1X10<6>mol.wt. and a water-soluble polyhydroxy compd. exhibits an excellent surface-active function, and a solubilizing soln. or an emulsion can be obtained by the function.
TANGO2-related disorder is a rare autosomal recessive genetic disorder that can cause recurrent rhabdomyolysis and life-threatening cardiac arrhythmias. Metabolic crises can be triggered by prolonged fasting and dehydration. Intellectual disability, seizures, hypothyroidism, and gait abnormalities are observed frequently. The function of TANGO2 is unknown and the pathogenesis of this disease is poorly understood. Understanding disease mechanism requires studying disease cells/samples and thus establishing a biobank of tissues (blood and fibroblasts) of individuals affected with TANGO2 deficiency is paramount. Natural History Study of TANGO2-related disorder will allow investigators to understand the course of the disease and develop new therapies in the future to decrease morbidity associated with this genetic condition.
AIM: Pancreatic cancer (PC) has a poor prognosis and high mortality. Kruppel-like factor 9 (KLF9), a transcription factor, is aberrantly expressed in various neoplasms. The current study sought to analyze the functional role of KLF9 in the proliferation, invasion, and migration of PC cells.
METHODS: The expression patterns of KLF9 and KIAA1522 in normal pancreatic cells (HPDE-C7) and PC cells (Panc 03.27, BxPc3, SW1990) were determined by real-time quantitative polymerase chain reaction and Western blot assay. After treatment of KLF9 overexpression, proliferation, invasion, and migration were evaluated by cell counting kit-8, 5-ethynyl-2'-deoxyuridine staining, and Transwell assays. The binding of KLF9 to the KIAA1522 promoter was analyzed by dual-luciferase assay and chromatin immunoprecipitation. The rescue experiment was conducted to analyze the role of KIAA1522.
RESULTS: KLF9 was downregulated, while KIAA1522 was upregulated in PC cells. KLF9 overexpression mitigated the proliferation, invasion, and migration of PC cells. Enrichment of KLF9 led to inhibition of the KIAA1522 promoter and repressed KIAA1522 expression. KIAA1522 overexpression neutralized the inhibitory role of KLF9 in PC cell functions.
CONCLUSION: KLF9 is enriched in the KIAA1522 promoter and negatively regulates KIAA1522 expression, thereby mitigating the proliferation, invasion, and migration of PC cells.
Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (\>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
2.1. Participants In all, 100 subjects were recruited to this clinical study according to the following inclusion criteria: i) Healthy male or female; ii) presence of \>20 existing teeth (the number of remaining teeth); iii) no severe pathological soft tissue conditions, periodontitis, or extensive dental plaque; iv) Turesky modification of the Quigley-Hein Plaque Index (PI) of over 1.5 and Loe \& Silness Gingival Index (GI) of over 1.5; vi) able to perform oral care/hygiene tasks on his/her own; vii) voluntary participation; and viii) willing to comply with the test protocol. Participants were excluded if they had any kind of visible or known disease requiring prophylactic antibiotic use.

2.2. Study design This was a randomized, controlled, double-blind clinical trial, and the intervention was gargling with the OR twice daily. The participants were randomly divided into four groups: control 1 (C1) (n=19), immediate-use CPC (IUC) (n=16), control 2 (C2) (n=19), and concentrated-use CPC (CUC) groups (n=19). Both C1 and C2 received ORs without CPC, whereas the experimental groups IUC and CUC received CPC ORs of different formulations (Amway Korea Ltd., Seoul, Republic of Korea). Randomized clinical trials (RCTs) are analyzed according to the intention-to-treat (ITT) principle and the per-protocol (PP) approach. ITT aims to assess the experimental design and PP analysis investigates the effect of receiving an assigned treatment. The participants underwent dental scaling before starting the intervention. Ethical approval was granted by the Institutional Research Ethics Review Board, Yonsei University, Wonju Severance Christian Hospital (IRBN CR321058) 2.3. Intervention After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hours before the visit.

2.4. Measurment of H2S and methyl mercaptan, Quigley-Hein plaque index, Gingival Index,Tongue Coating Index.
The invention relates to a capsule for receiving a preferably powdery pharmaceutical preparation and to an inhalator in which, for inhalation, the preparation exits the capsule through at least one hole. A capsule according to the invention has as capsule element, a capsule cap, and a capsule body, of which at least one has a prefabricated hole. Systems according to the invention comprise an inhalator and a capsule, wherein the prefabricated hole in the capsule is sealed in the transport state of the system, and open in the usage state. By activating a push or pull mechanism, the hole is opened. Prior to this, the hole is closed by a portion of the capsule itself or by a capsule receptacle that is part of the inhalator. In one embodiment, the capsule can be in two different states, for example, in different inserted positions of the capsule elements. In the first state, the prefabricated hole is closed, and in the second state it is open. A further system according to the invention consists of a capsule body that is open at the top and an inhalator, wherein the capsule which is open at the top in such a way is filled inside the inhalator.
Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle. And on start day of induction ( Day 2 to 3) until the day of the human chorionic gonadotropin (hCG) trigger.
Exposure to cigarette smoke is known to induce disease during pregnancy. Recent evidence showed that exposure to secondhand smoke (SHS) negatively impacts fetal and placental weights, leading to the development of intrauterine growth restriction (IUGR). Electronic cigarettes (eCigs) represent a phenomenon that has recently emerged, and their use is also steadily rising. Even so, the effects of SHS or eCigs during gestation remain limited. In the present study, we wanted to characterize the effects of SHS or eCig exposure at two different important gestational points during mouse pregnancy. C57/Bl6 mice were exposed to SHS or eCigs via a nose-only delivery system for 4 days (from 14.5 to 17.5 gestational days (dGA) or for 6 days (from 12.5 dGA to 17.5 dGA)). At the time of necropsy (18.5 dGA), placental and fetal weights were recorded, maternal blood pressure was determined, and a dipstick test to measure proteinuria was performed. Placental tissues were collected, and inflammatory molecules in the placenta were identified. Treatment with SHS showed the following: (1) a significant decrease in placental and fetal weights following four days of exposure, (2) higher systolic and diastolic blood pressure following six days of exposure, and (3) increased proteinuria after six days of exposure. Treatment with eCigs showed the following: (1) a significant decrease in placental weight and fetal weight following four or six days of exposure, (2) higher systolic and diastolic blood pressure following six days of exposure, and (3) increased proteinuria after six days of exposure. We also observed different inflammatory markers associated with the development of IUGR or PE. We conclude that the detrimental effects of SHS or eCig treatment coincide with the length of maternal exposure. These results could be beneficial in understanding the long-term effects of SHS or eCig exposure in the development of placental diseases.
This study explored the mechanism of the ultrafiltration extract of Angelicae Sinensis Radix and Hedysari Radix in ameliorating renal fibrosis in the rat model of diabetic kidney disease(DKD) based on the expression of hypoxia-inducible factor-1α(HIF-1α)/vascular endothelial growth factor(VEGF) and HIF-1α/platelet-derived growth factor(PDGF)/platelet-derived growth factor receptor(PDGFR) signaling pathways in the DKD rats. After 1 week of adaptive feeding, 50 male SPF-grade Wistar rats were randomized into a blank group(n=7) and a modeling group. After 24 h of fasting, the rats in the modeling group were subjected to intraperitoneal injection of streptozocin and fed with a high-sugar and high-fat diet to establish a DKD model. After modeling, the rats were randomly assigned into model(n=7), low-dose ultrafiltration extract(n=7), medium-dose ultrafiltration extract(n=7), irbesartan(n=8), and high-dose ultrafiltration extract(n=8) groups. After intervention by corresponding drugs for 12 weeks, the general conditions of the rats were observed. The body weights and blood glucose levels of the rats were measured weekly, and the 24 h urinary protein(24hUP) was measured at the 6th and 12th weeks of drug administration. After the last drug administration, the renal function indicators were determined. Masson staining was employed to observe the pathological changes of the renal tissue. The expression of prolyl hydroxylase domain 2(PHD2) and HIF-1α in the renal tissue was detected by immunohistochemistry(IHC). Real-time qPCR was employed to determine the mRNA levels of PHD2, VEGF, PDGF, and PDGFR in the renal tissue. Western blot was employed to determine the protein levels of HIF-1α, VEGF, PDGF, and PDGFR in the renal tissue. The results showed that compared with the model group, drug administration lowered the levels of glycosylated serum protein(GSP), aerum creatinine(Scr), and blood urea nitrogen(BUN) in a dose-dependent manner(P<0.05 or P<0.01) and mitigated the pathological changes in the renal tissue. Furthermore, drug administration up-regulated mRNA level of PHD2(P<0.05 or P<0.01), down-regulated the mRNA levels of VEGF, PDGF, and PDGFR(P<0.05 or P<0.01) and the protein levels of HIF-1α, VEGF, PDGF, and PDGFR(P<0.01) in the renal tissue, and increased the rate of PHD2-positive cells(P<0.01). In conclusion, the ultrafiltration extract of Angelicae Sinensis Radix and Hedysari Radix effectively alleviated the renal fibrosis in DKD rats by inhibiting the expression of key proteins in the HIF-1α signaling pathway mediated by renal hypoxia and reducing extracellular matrix(ECM) deposition.
BACKGROUND: Children living with HIV/AIDS are particularly vulnerable to under-nutrition. Under-nutrition associated with HIV/AIDS infection increases the rate of morbidity and mortality in children. To reaffirm a future objective, there needs to be evidence regarding the current national burden of under-nutrition and related factors among children infected with HIV. Hence, the objective of this systematic review and meta-analysis was to estimate the pooled prevalence of under-nutrition, and the pooled effect sizes of associated factors among HIV-infected children in Ethiopia.
METHODS: We searched Ethiopian universities' online libraries, Google, Google Scholar, PubMed, CINAHL, Cochrane Library, and Scopus to find the primary studies for this review. Publication bias was checked through Egger's regression test. Heterogeneity among the included studies was assessed using the I2 test. The data were extracted using Microsoft Excel and exported to STATA Version 14 statistical software. A random effect meta-analysis model was performed to estimate the pooled prevalence of Under-nutrition.
RESULTS: After reviewing 1449 primary studies, 16 articles met the inclusion criteria and were included in the final meta-analysis. The estimated pooled prevalence of stunting, underweight, and wasting among children living with HIV/AIDS was 32.98% (95% CI: 22.47, 43.50), 29.76% (95% CI: 21.87, 37.66), and 21.16% (95% CI: 14.96, 27.35) respectively.
CONCLUSIONS: This study showed that under-nutrition among HIV-infected children in Ethiopia was significantly high. Under-nutrition is more common among HIV-infected children with opportunistic infections, child feeding problems, do not adhere to dietary recommendations, and have diarrhea. The national policies and strategies for ART service- provider centers should maximize their emphasis on reducing under-nutrition among HIV-infected children. Based on this finding, we recommend HIV intervention programs to address nutritional assessment and interventions for HIV-infected children.
PROTOCOL REGISTRATION: The protocol has been registered in the PROSPERO database with a registration number of CRD-394170.
Ultrasound-guided nerve blocks (UGNBs) are becoming a more common method for pain control in the emergency department. Specifically, brachial plexus blocks have shown promise for acute upper extremity injuries as well as an alternative to procedural sedation for glenohumeral reductions. Unfortunately, there is minimal discussion in the EM literature regarding phrenic nerve paralysis (a well-known complication from brachial plexus blocks). The anatomy of the brachial plexus, its relationship to the phrenic nerve, and why ultrasound-guided brachial plexus blocks can cause phrenic nerve paralysis and resultant respiratory impairment will be discussed. The focus on patient safety is paramount, and those with preexisting respiratory conditions, extremes of age or weight, spinal deformities, previous neck injuries, and anatomical variations are at greater risk. We put forth different block strategies for risk mitigation, including patient selection, volume and type of anesthetic, block location, postprocedural monitoring, and specific discharge instructions. Understanding the benefits and risks of UGNBs is critical for emergency physicians to provide effective pain control while ensuring optimal patient safety.
This study aims to investigate the regulatory effects of quercetin extracellular vesicles (EVs)-mediated expression of vascular endothelial growth factor receptor 2 (VEGFR2) in hepatocellular carcinoma (HCC)-derived circulating tumor cells (CTCs) and the underlying mechanisms. CTCs were isolated from patients with pathologically diagnosed HCC, with VEGFR2 expression visualized by fluorescence in situ hybridization (FISH). The human HCC cell line Huh-7 and SK-HEP-1 were used for in vitro studies to assess EVs uptake, VEGFR2 mRNA transfer, invasion, migration, cancer stem cell (CSC) properties, and VEGF secretion. Results showed that VEGFR2 mRNA was commonly expressed in HCC-CTCs, with a higher incidence in biphenotypic CTCs. Its expression was limited in HCC cell lines, but present in certain liver cells. In vitro experiments confirmed that VEGFR2 mRNA could be transferred to HCC cells via EVs from primary tumor endothelial cells (PTECs), which was impaired by quercetin treatment. Quercetin significantly reduced VEGFR2 mRNA and protein expression in HCC cells, weakened their invasive and metastatic capacities, and diminished VEGFR2-mediated CSC properties. In vivo, quercetin reduced VEGF secretion, impaired angiogenesis, slowed tumor growth, and decreased the number and proportion of VEGFR2-positive CTCs. In summary, VEGFR2 mRNA is present in HCC-CTCs, potentially sourced from PTECs-derived EVs. Quercetin effectively inhibits VEGFR2 expression, impacting HCC cell invasion, metastasis, and CSC characteristics. Besides, it reduces VEGFR2-positive CTCs in vivo. These effects support its therapeutic potential in HCC treatment by targeting the angiogenesis and tumor dissemination pathway.
Patients receive niraparib PO QD on days 1-21. Patients also receive dostarlimab IV over 30 minutes on day 1 Q3W for cycles 1-4 and Q6W for subsequent cycles. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
1,235,667. Prolonged release medicaments. NATIONAL RESEARCH DEVELOPMENT CORP. 8 July, 1968 [19 July, 1967; 15 May, 1968], Nos. 33255/67 and 23146/68. Heading A5B. An injectable medicament having prolonged release is formulated by preparing a primary water-in-oil emulsion containing a watersoluble, sparing oil-soluble, active substance (which is not solely or primarily antigenic) and another physiologically acceptable substance, e.g. NaCl or glucose, in the aqueous phase, the quantities thereof being such that the osmolarity of the aqueous medium and internal phase volume of the emulsion, together with the concentration of detergent used to prepare the emulsion are so selected that prolonged release of the active substance is achieved in vivo when the primary emulsion is injected in the form of a double emulsion in an outermost aqueous phase. A wide range of active substances are referred to including antibiotics, vitamins, chemotherapeutics, anti-coagulants and alkaloids.
PROBLEM TO BE SOLVED: To obtain a lipid aggregate which is specifically selectively transferred into lymph system, especially lymph node and manifests anti-HIV activity by making the lipid aggregate include a specific lipid analogue type compound into a fat-soluble microparticle carrier. SOLUTION: This lipid aggregate is obtained by including (A) a lipid analogue type compound represented by formula I  R1 is a long-chain fatty acid residue, etc.; R2 is H, a hydrocarbon residue, etc.; X is a group of formula II [R3 is H or azide; R4 is H or a lower alkyl; Y is a base represented by formula III, formula IV or formula V (R5 is a halogen, etc.; R6 is a lower alkyl, etc.; R7 is amino, etc.; R8 is a halogen, etc.; R9 is an amino, etc.)], and developing anti- HIV activity in the presence of at least phospholipase D or C into (B) a fat- soluble microparticle carrier (e.g. liposome or emulsion). The component A is preferably contained in an amount of usually 10-100 mol.% based on the component B in the above aggregate.
The invention discloses a carbon nanosphere preparation as well as a preparation method and an anti-helicobacter pylori infection experiment method thereof. The carbon nanosphere preparation is prepared by mixing carbon nanospheres and dispersion liquid; the concentration of the carbon nanosphere preparation is 0.1 percent to 1.0 percent; the dispersion liquid is de-ionized water and the grain diameter of not less than 95 percent of the carbon nanospheres is 5nm to 30nm. The carbon nanosphere preparation has the advantages of low cost, easiness for manufacturing, good stability, high safety and good anti-helicobacter pylori infection effect. The preparation method of the carbon nanosphere preparation has the characteristics of easiness of implementation, simple process and convenience for operation. The anti-helicobacter pylori infection experiment method of the carbon nanosphere preparation has the characteristics of convenience for implementation, scientificity and rationality. The carbon nanosphere preparation disclosed by the invention can be developed as a new drug for treating helicobacter pylori infection, so that a new idea is provided for developing anti-helicobacter pylori infection medicines and a new strategy is provided for prevention and treatment of anti-helicobacter pylori infection.